Bioventus reports Q3 net sales $120.8M (-6.1% YoY), raises 2023 adjusted EBITDA guidance

Bioventus Inc.

2023-Q3 EPS reported -$2.40 revenue$376,922,000

Net loss from continuing ops improved to $8.8M from $101.0M in Q3 2022; loss per share $0.12 vs $1.18.
Adjusted EBITDA from continuing ops $21.7M, down 0.9% YoY; non-GAAP EPS $0.05 vs $0.18.
Pain Treatments revenue grew 3.1% YoY to $53.7M; Surgical Solutions up 5.7% in U.S.
Raised full-year 2023 guidance: net sales $498-505M, adjusted EBITDA $84-87M.
Restorative Therapies fell 34.8% due to Wound Business divestiture; underlying organic sales down 0.5%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Bioventus Inc. reported the three and nine months ended September 30, 2023 results: revenue $120.8 million, net income Net Loss from continuing operations of $8.8 million, EPS Loss per share of Class A common stock from continuing operations of $0.12. Guidance raised.

Period: the three and nine months ended September 30, 2023
Revenue: $120.8 million
Net income: Net Loss from continuing operations of $8.8 million
EPS: Loss per share of Class A common stock from continuing operations of $0.12
Guidance: raised
Result: reported results

Exact text from the filing

a global leader in innovations for active healing, today reported financial results for the three and nine months ended September 30, 2023. Q3 Financial Summary: • Net Sales of $120.8 million, down $7.9 million, or 6.1%, year-over-year as reported (6.3% constant currency*). Excluding revenues from divested wound assets, underlying organic sales decreased $0.6 million,

View on SEC.gov

Browse all earnings releases →

Bioventus Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-037183

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.